Al and Deborah standing outside
Al and Deborah standing outside

_

FEEL MORE IN THE MOMENT1-3

AMVUTTRA® (vutrisiran) is the only treatment that can reverse the polyneuropathy manifestations of hATTR amyloidosis with 4 doses per year1-4,a

AL, treated with AMVUTTRA, and DEBORAH, his spouse and caregiver

AL, treated with AMVUTTRA, 
and DEBORAH, his spouse and caregiver

At 9 months in a randomized, open-label study, patients treated with AMVUTTRA were compared with an external placebo group and demonstrated1,2:

hcp knockdown

Rapid knockdown
of TTR as early as 3 weeks1,2,b

Improvement in neuropathy impairment, as measured by mNIS+71,2

mNIS+7=modified Neuropathy Impairment Score + 7.

Improvement in quality of life, as measured by Norfolk QoL-DN1,2

Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy.

Improvement in gait speed, as measured by 10MWT1

10MWT=10-meter walk test.

aAdministered once every 3 months.

bFirst measured at 3 weeks.

10MWT=10-meter walk test; mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy.

More than 1,300 patients are receiving treatment with AMVUTTRA in the US, making it the #1-prescribed treatment for the polyneuropathy of hATTR amyloidosis in adults.5

Explore the pivotal study design and the efficacy and safety of AMVUTTRA

Clinical profile

Learn how to administer AMVUTTRA

Dosing and administration

Find out how to get your patients started with AMVUTTRA

Get started with AMVUTTRA
Find a treatment center
Find a treatment center

Locate a treatment center closest to your patients.

View the directory
Stay informed
Stay informed

Receive helpful information for you and your patients.

Sign up

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Adams D, Tournev IL, Taylor MS, et al. Amyloid. 2023;30(1):18-26.
  3. ONPATTRO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  4. WAINUA Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  5. Data on file. Alnylam Pharmaceuticals, Inc.